+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Neurodegenerative Drugs Market - Global Forecast 2026-2032- Product Image
Neurodegenerative Drugs Market - Global Forecast 2026-2032- Product Image
New

Neurodegenerative Drugs Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 181 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 5888919
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The neurodegenerative drugs market is advancing rapidly in response to complex patient needs, emerging technologies, and a growing burden of age-related neurological conditions. Driven by innovation, stakeholder collaboration, and an evolving policy landscape, senior leaders must strategically position within this dynamic environment to secure long-term growth.

Market Snapshot

The global neurodegenerative drugs market expanded from USD 47.79 billion in 2025 to USD 51.39 billion in 2026 and is projected to reach USD 81.51 billion by 2032, reflecting a CAGR of 7.92%. Growth is fueled by aging global populations, increased prevalence of neurodegenerative diseases, and accelerated by advanced research in gene therapy, regenerative medicine, and digital health integration.

Scope & Segmentation

  • Product Types: Includes branded and generic neurodegenerative therapies.
  • Drug Classes: Covers cholinesterase inhibitors, decarboxylase inhibitors, dopamine agonists, and immunomodulatory agents.
  • Mechanism of Action: Encompasses synaptic modulators, potassium and sodium channel modulators.
  • Therapeutic Approaches: Ranges from neuroprotection, anti-inflammatory agents, antioxidants, disease prevention, and symptomatic interventions.
  • Mode of Administration: Features injectable, oral, and transdermal drug delivery options.
  • Indications: Focuses on Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), multiple sclerosis (primary progressive and relapsing-remitting), and Parkinson’s disease.
  • Patient Demographics: Considers adult, geriatric, and pediatric populations.
  • Sales Channels: Differentiates between offline channels (hospital and retail pharmacies) and online platforms.
  • End Users: Encompasses clinics, contract research organizations, hospitals, and research institutes.
  • Regions: Assesses Americas, Europe-Middle East-Africa, and Asia-Pacific geographies for market opportunity and adoption trends.
  • Technology Integration: Includes gene editing (CRISPR), machine learning, artificial intelligence, regenerative therapies (e.g., induced pluripotent stem cells), and digital health platforms.

Key Takeaways

  • New therapeutic pathways have emerged through advancements in high-throughput screening, omics, and computational biology, driving drug discovery efficiency.
  • Regulatory frameworks increasingly support accelerated approvals for innovations addressing high unmet need, streamlining the journey from bench to bedside.
  • Industry developments show a rising emphasis on patient-centric clinical trials, where adaptive trial designs and real-world evidence enable rapid insights into drug performance.
  • Strategic alliances between pharmaceutical and biotech firms foster robust, diversified pipelines, integrating small molecules, biologics, gene therapies, and combination regimens.
  • End-user demand is distributed across clinics, hospitals, CROs, and research institutes, underlining the need for customized market approaches to maximize uptake.

Tariff Impact

Recent United States tariff policies on critical pharmaceutical components have reshaped global supply chains by increasing production costs and complexity. Companies are responding by investing in domestic sourcing, exploring alternative trade routes, and vertically integrating manufacturing to enhance resilience. These developments heighten the importance of adaptive procurement strategies and transparent pricing negotiations with payers and health systems to maintain therapy access and support innovation.

Methodology & Data Sources

The research combines extensive secondary analysis, including peer-reviewed literature, clinical registries, regulatory filings, and patent landscapes, with primary interviews of neurologists, pharmacologists, regulatory experts, and industry executives. A rigorous approach to data triangulation, peer review, and consistency checking ensures accuracy, relevance, and actionable insights for decision-makers.

Why This Report Matters

  • Enables executives to identify emerging therapeutic opportunities, technology trends, and market entry points for strategic planning.
  • Supports mitigation of supply chain and regulatory risks through analysis of trade policy impacts and adaptive strategies.
  • Delivers nuanced insights into rapidly evolving segmentation and regional dynamics, empowering leadership to target investments for maximum growth potential.

Conclusion

Positioned at the intersection of innovation, collaboration, and market complexity, the neurodegenerative drugs sector demands agile and informed strategies. Senior leaders equipped with targeted analysis can navigate uncertainty and capitalize on transformative opportunities within this evolving therapeutic landscape.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Neurodegenerative Drugs Market, by Type
8.1. Branded
8.2. Generics
9. Neurodegenerative Drugs Market, by Drug Class
9.1. Cholinesterase Inhibitors
9.1.1. Donepezil
9.1.2. Pyridostigmine
9.1.3. Rivastigmine
9.2. Decarboxylase Inhibitors
9.2.1. Benserazide
9.2.2. Carbidopa
9.2.3. Methyldopa
9.3. Dopamine Agonist
9.3.1. Apomorphine
9.3.2. Cabergoline
9.3.3. Pramipexole
9.3.4. Rotigotine
9.4. Immunomodulators
10. Neurodegenerative Drugs Market, by Mode Of Administration
10.1. Injectable
10.2. Oral
10.3. Transdermal Patch
11. Neurodegenerative Drugs Market, by Mechanism Of Action
11.1. Ion Channel Modulators
11.1.1. Potassium Channel Modulators
11.1.2. Sodium Channel Modulators
11.2. Synaptic Modulators
12. Neurodegenerative Drugs Market, by Therapeutic Approach
12.1. Neuroprotection
12.1.1. Anti-Inflammatory Agents
12.1.2. Antioxidants
12.2. Preventive Treatment
12.3. Symptomatic Treatment
13. Neurodegenerative Drugs Market, by Indication
13.1. Alzheimer's Disease
13.2. Amyotrophic Lateral Sclerosis (ALS)
13.3. Multiple Sclerosis
13.3.1. Primary Progressive
13.3.2. Relapsing-Remitting
13.4. Parkinson's Disease
14. Neurodegenerative Drugs Market, by Patient Demographics
14.1. Adult
14.2. Geriatric
14.3. Pediatric
15. Neurodegenerative Drugs Market, by Sales Channel
15.1. Offline
15.1.1. Hospitals Pharmacies
15.1.2. Retail Pharmacies
15.2. Online
16. Neurodegenerative Drugs Market, by End User
16.1. Clinics
16.2. Contract Research Organizations
16.3. Hospitals
16.4. Research Institutes
17. Neurodegenerative Drugs Market, by Region
17.1. Americas
17.1.1. North America
17.1.2. Latin America
17.2. Europe, Middle East & Africa
17.2.1. Europe
17.2.2. Middle East
17.2.3. Africa
17.3. Asia-Pacific
18. Neurodegenerative Drugs Market, by Group
18.1. ASEAN
18.2. GCC
18.3. European Union
18.4. BRICS
18.5. G7
18.6. NATO
19. Neurodegenerative Drugs Market, by Country
19.1. United States
19.2. Canada
19.3. Mexico
19.4. Brazil
19.5. United Kingdom
19.6. Germany
19.7. France
19.8. Russia
19.9. Italy
19.10. Spain
19.11. China
19.12. India
19.13. Japan
19.14. Australia
19.15. South Korea
20. United States Neurodegenerative Drugs Market
21. China Neurodegenerative Drugs Market
22. Competitive Landscape
22.1. Market Concentration Analysis, 2025
22.1.1. Concentration Ratio (CR)
22.1.2. Herfindahl Hirschman Index (HHI)
22.2. Recent Developments & Impact Analysis, 2025
22.3. Product Portfolio Analysis, 2025
22.4. Benchmarking Analysis, 2025
22.5. Abbott Laboratories
22.6. AbbVie Inc.
22.7. ACADIA Pharmaceuticals Inc.
22.8. Alpha Cognition Inc.
22.9. Amneal Pharmaceuticals, Inc.
22.10. Aquinnah Pharmaceuticals Inc.
22.11. Asceneuron SA
22.12. AstraZeneca PLC
22.13. AZTherapies, Inc.
22.14. Bausch Health Companies Inc.
22.15. Biogen Inc.
22.16. Boehringer Ingelheim International GmbH
22.17. Denali Therapeutics Inc.
22.18. Eli Lilly and Company
22.19. GlaxoSmithKline PLC
22.20. H. Lundbeck A/S
22.21. Johnson & Johnson Services, Inc.
22.22. Kyowa Kirin International plc
22.23. Lupin Limited
22.24. Merck & Co., Inc.
22.25. Novartis AG
22.26. Orion Corporation by Smiths Group plc
22.27. Pfizer, Inc.
22.28. Sanofi SA
22.29. Takeda Pharmaceutical Company Limited
22.30. Theravance Biopharma
22.31. UCB S.A.
List of Figures
FIGURE 1. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL NEURODEGENERATIVE DRUGS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL NEURODEGENERATIVE DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY THERAPEUTIC APPROACH, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 13. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 15. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 17. CHINA NEURODEGENERATIVE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY BRANDED, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY BRANDED, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY BRANDED, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY GENERICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY GENERICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY GENERICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY DONEPEZIL, BY REGION, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY DONEPEZIL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY DONEPEZIL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY PYRIDOSTIGMINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY PYRIDOSTIGMINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY PYRIDOSTIGMINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY RIVASTIGMINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY RIVASTIGMINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY RIVASTIGMINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY DECARBOXYLASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY DECARBOXYLASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY DECARBOXYLASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY DECARBOXYLASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY BENSERAZIDE, BY REGION, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY BENSERAZIDE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY BENSERAZIDE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY CARBIDOPA, BY REGION, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY CARBIDOPA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY CARBIDOPA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY METHYLDOPA, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY METHYLDOPA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY METHYLDOPA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY DOPAMINE AGONIST, BY REGION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY DOPAMINE AGONIST, BY GROUP, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY DOPAMINE AGONIST, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY DOPAMINE AGONIST, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY APOMORPHINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY APOMORPHINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY APOMORPHINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY CABERGOLINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY CABERGOLINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY CABERGOLINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY PRAMIPEXOLE, BY REGION, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY PRAMIPEXOLE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY PRAMIPEXOLE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ROTIGOTINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ROTIGOTINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ROTIGOTINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY IMMUNOMODULATORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY IMMUNOMODULATORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY IMMUNOMODULATORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY TRANSDERMAL PATCH, BY REGION, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY TRANSDERMAL PATCH, BY GROUP, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY TRANSDERMAL PATCH, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ION CHANNEL MODULATORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ION CHANNEL MODULATORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ION CHANNEL MODULATORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ION CHANNEL MODULATORS, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY POTASSIUM CHANNEL MODULATORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY POTASSIUM CHANNEL MODULATORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY POTASSIUM CHANNEL MODULATORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY SODIUM CHANNEL MODULATORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY SODIUM CHANNEL MODULATORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY SODIUM CHANNEL MODULATORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY SYNAPTIC MODULATORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY SYNAPTIC MODULATORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY SYNAPTIC MODULATORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY NEUROPROTECTION, BY REGION, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY NEUROPROTECTION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY NEUROPROTECTION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY NEUROPROTECTION, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ANTIOXIDANTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ANTIOXIDANTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ANTIOXIDANTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY PREVENTIVE TREATMENT, BY REGION, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY PREVENTIVE TREATMENT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY PREVENTIVE TREATMENT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY SYMPTOMATIC TREATMENT, BY REGION, 2018-2032 (USD MILLION)
TABLE 94. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY SYMPTOMATIC TREATMENT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 95. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY SYMPTOMATIC TREATMENT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 96. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 97. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ALZHEIMER'S DISEASE, BY REGION, 2018-2032 (USD MILLION)
TABLE 98. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ALZHEIMER'S DISEASE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 99. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ALZHEIMER'S DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 100. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY AMYOTROPHIC LATERAL SCLEROSIS (ALS), BY REGION, 2018-2032 (USD MILLION)
TABLE 101. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY AMYOTROPHIC LATERAL SCLEROSIS (ALS), BY GROUP, 2018-2032 (USD MILLION)
TABLE 102. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY AMYOTROPHIC LATERAL SCLEROSIS (ALS), BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 103. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2032 (USD MILLION)
TABLE 104. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 105. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 106. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2032 (USD MILLION)
TABLE 107. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY PRIMARY PROGRESSIVE, BY REGION, 2018-2032 (USD MILLION)
TABLE 108. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY PRIMARY PROGRESSIVE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 109. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY PRIMARY PROGRESSIVE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 110. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY RELAPSING-REMITTING, BY REGION, 2018-2032 (USD MILLION)
TABLE 111. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY RELAPSING-REMITTING, BY GROUP, 2018-2032 (USD MILLION)
TABLE 112. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY RELAPSING-REMITTING, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 113. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2018-2032 (USD MILLION)
TABLE 114. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY PARKINSON'S DISEASE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 115. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY PARKINSON'S DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 116. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
TABLE 117. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
TABLE 118. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 119. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 120. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2032 (USD MILLION)
TABLE 121. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2032 (USD MILLION)
TABLE 122. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 123. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
TABLE 124. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
TABLE 125. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 126. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
TABLE 127. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 128. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 129. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 130. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
TABLE 131. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY HOSPITALS PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 132. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY HOSPITALS PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 133. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY HOSPITALS PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 134. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 135. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 136. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 137. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 138. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 139. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 140. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 141. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 142. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 143. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 144. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
TABLE 145. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 146. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 147. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 148. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 149. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 150. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
TABLE 151. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 152. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 153. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 154. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 155. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 156. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 157. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 158. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY DECARBOXYLASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 159. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY DOPAMINE AGONIST, 2018-2032 (USD MILLION)
TABLE 160. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 161. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 162. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY ION CHANNEL MODULATORS, 2018-2032 (USD MILLION)
TABLE 163. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2032 (USD MILLION)
TABLE 164. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY NEUROPROTECTION, 2018-2032 (USD MILLION)
TABLE 165. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 166. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2032 (USD MILLION)
TABLE 167. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
TABLE 168. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
TABLE 169. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
TABLE 170. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 171. NORTH AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 172. NORTH AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 173. NORTH AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 174. NORTH AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 175. NORTH AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY DECARBOXYLASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 176. NORTH AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY DOPAMINE AGONIST, 2018-2032 (USD MILLION)
TABLE 177. NORTH AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 178. NORTH AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 179. NORTH AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY ION CHANNEL MODULATORS, 2018-2032 (USD MILLION)
TABLE 180. NORTH AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2032 (USD MILLION)
TABLE 181. NORTH AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY NEUROPROTECTION, 2018-2032 (USD MILLION)
TABLE 182. NORTH AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 183. NORTH AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2032 (USD MILLION)
TABLE 184. NORTH AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
TABLE 185. NORTH AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
TABLE 186. NORTH AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
TABLE 187. NORTH AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 188. LATIN AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 189. LATIN AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 190. LATIN AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 191. LATIN AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 192. LATIN AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY DECARBOXYLASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 193. LATIN AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY DOPAMINE AGONIST, 2018-2032 (USD MILLION)
TABLE 194. LATIN AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 195. LATIN AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 196. LATIN AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY ION CHANNEL MODULATORS, 2018-2032 (USD MILLION)
TABLE 197. LATIN AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2032 (USD MILLION)
TABLE 198. LATIN AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY NEUROPROTECTION, 2018-2032 (USD MILLION)
TABLE 199. LATIN AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 200. LATIN AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2032 (USD MILLION)
TABLE 201. LATIN AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
TABLE 202. LATIN AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
TABLE 203. LATIN AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
TABLE 204. LATIN AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 205. EUROPE, MIDDLE EAST & AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 206. EUROPE, MIDDLE EAST & AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 207. EUROPE, MIDDLE EAST & AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 208. EUROPE, MIDDLE EAST & AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 209. EUROPE, MIDDLE EAST & AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY DECARBOXYLASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 210. EUROPE, MIDDLE EAST & AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY DOPAMINE AGONIST, 2018-2032 (USD MILLION)
TABLE 211. EUROPE, MIDDLE EAST & AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 212. EUROPE, MIDDLE EAST & AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 213. EUROPE, MIDDLE EAST & AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY ION CHANNEL MODULATORS, 2018-2032 (USD MILLION)
TABLE 214. EUROPE, MIDDLE EAST & AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2032 (USD MILLION)
TABLE 215. EUROPE, MIDDLE EAST & AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY NEUROPROTECTION, 2018-2032 (USD MILLION)
TABLE 216. EUROPE, MIDDLE EAST & AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 217. EUROPE, MIDDLE EAST & AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2032 (USD MILLION)
TABLE 218. EUROPE, MIDDLE EAST & AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
TABLE 219. EUROPE, MIDDLE EAST & AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
TABLE 220. EUROPE, MIDDLE EAST & AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
TABLE 221. EUROPE, MIDDLE EAST & AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 222. EUROPE NEURODEGENERATIVE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 223. EUROPE NEURODEGENERATIVE DRUGS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 224. EUROPE NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 225. EUROPE NEURODEGENERATIVE DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 226. EUROPE NEURODEGENERATIVE DRUGS MARKET SIZE, BY DECARBOXYLASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 227. EUROPE NEURODEGENERATIVE DRUGS MARKET SIZE, BY DOPAMINE AGONIST, 2018-2032 (USD MILLION)
TABLE 228. EUROPE NEURODEGENERATIVE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 229. EUROPE NEURODEGENERATIVE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 230. EUROPE NEURODEGENERATIVE DRUGS MARKET SIZE, BY ION CHANNEL MODULATORS, 2018-2032 (USD MILLION)
TABLE 231. EUROPE NEURODEGENERATIVE DRUGS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2032 (USD MILLION)
TABLE 232. EUROPE NEURODEGENERATIVE DRUGS MARKET SIZE, BY NEUROPROTECTION, 2018-2032 (USD MILLION)
TABLE 233. EUROPE NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 234. EUROPE NEURODEGENERATIVE DRUGS MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2032 (USD MILLION)
TABLE 235. EUROPE NEURODEGENERATIVE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
TABLE 236. EUROPE NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
TABLE 237. EUROPE NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
TABLE 238. EUROPE NEURODEGENERATIVE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 239. MIDDLE EAST NEURODEGENERATIVE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 240. MIDDLE EAST NEURODEGENERATIVE DRUGS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 241. MIDDLE EAST NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 242. MIDDLE EAST NEURODEGENERATIVE DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 243. MIDDLE EAST NEURODEGENERATIVE DRUGS MARKET SIZE, BY DECARBOXYLASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 244. MIDDLE EAST NEURODEGENERATIVE DRUGS MARKET SIZE, BY DOPAMINE AGONIST, 2018-2032 (USD MILLION)
TABLE 245. MIDDLE EAST NEURODEGENERATIVE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 246. MIDDLE EAST NEURODEGENERATIVE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 247. MIDDLE EAST NEURODEGENERATIVE DRUGS MARKET SIZE, BY ION CHANNEL MODULATORS, 2018-2032 (USD MILLION)
TABLE 248. MIDDLE EAST NEURODEGENERATIVE DRUGS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2032 (USD MILLION)
TABLE 249. MIDDLE EAST NEURODEGENERATIVE DRUGS MARKET SIZE, BY NEUROPROTECTION, 2018-2032 (USD MILLION)
TABLE 250. MIDDLE EAST NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 251. MIDDLE EAST NEURODEGENERATIVE DRUGS MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2032 (USD MILLION)
TABLE 252. MIDDLE EAST NEURODEGENERATIVE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
TABLE 253. MIDDLE EAST NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
TABLE 254. MIDDLE EAST NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
TABLE 255. MIDDLE EAST NEURODEGENERATIVE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 256. AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 257. AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 258. AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 259. AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 260. AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY DECARBOXYLASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 261. AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY DOPAMINE AGONIST, 2018-2032 (USD MILLION)
TABLE 262. AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 263. AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 264. AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY ION CHANNEL MODULATORS, 2018-2032 (USD MILLION)
TABLE 265. AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2032 (USD MILLION)
TABLE 266. AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY NEUROPROTECTION, 2018-2032 (USD MILLION)
TABLE 267. AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 268. AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2032 (USD MILLION)
TABLE 269. AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
TABLE 270. AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
TABLE 271. AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
TABLE 272. AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 273. ASIA-PACIFIC NEURODEGENERATIVE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 274. ASIA-PACIFIC NEURODEGENERATIVE DRUGS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 275. ASIA-PACIFIC NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 276. ASIA-PACIFIC NEURODEGENERATIVE DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 277. ASIA-PACIFIC NEURODEGENERATIVE DRUGS MARKET SIZE, BY DECARBOXYLASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 278. ASIA-PACIFIC NEURODEGENERATIVE DRUGS MARKET SIZE, BY DOPAMINE AGONIST, 2018-2032 (USD MILLION)
TABLE 279. ASIA-PACIFIC NEURODEGENERATIVE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 280. ASIA-PACIFIC NEURODEGENERATIVE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 281. ASIA-PACIFIC NEURODEGENERATIVE DRUGS MARKET SIZE, BY ION CHANNEL MODULATORS, 2018-2032 (USD MILLION)
TABLE 282. ASIA-PACIFIC NEURODEGENERATIVE DRUGS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2032 (USD MILLION)
TABLE 283. ASIA-PACIFIC NEURODEGENERATIVE DRUGS MARKET SIZE, BY NEUROPROTECTION, 2018-2032 (USD MILLION)
TABLE 284. ASIA-PACIFIC NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 285. ASIA-PACIFIC NEURODEGENERATIVE DRUGS MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2032 (USD MILLION)
TABLE 286. ASIA-PACIFIC NEURODEGENERATIVE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
TABLE 287. ASIA-PACIFIC NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
TABLE 288. ASIA-PACIFIC NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
TABLE 289. ASIA-PACIFIC NEURODEGENERATIVE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 290. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 291. ASEAN NEURODEGENERATIVE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 292. ASEAN NEURODEGENERATIVE DRUGS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 293. ASEAN NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 294. ASEAN NEURODEGENERATIVE DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 295. ASEAN NEURODEGENERATIVE DRUGS MARKET SIZE, BY DECARBOXYLASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 296. ASEAN NEURODEGENERATIVE DRUGS MARKET SIZE, BY DOPAMINE AGONIST, 2018-2032 (USD MILLION)
TABLE 297. ASEAN NEURODEGENERATIVE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 298. ASEAN NEURODEGENERATIVE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 299. ASEAN NEURODEGENERATIVE DRUGS MARKET SIZE, BY ION CHANNEL MODULATORS, 2018-2032 (USD MILLION)
TABLE 300. ASEAN NEURODEGENERATIVE DRUGS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2032 (USD MILLION)
TABLE 301. ASEAN NEURODEGENERATIVE DRUGS MARKET SIZE, BY NEUROPROTECTION, 2018-2032 (USD MILLION)
TABLE 302. ASEAN NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 303. ASEAN NEURODEGENERATIVE DRUGS MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2032 (USD MILLION)
TABLE 304. ASEAN NEURODEGENERATIVE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
TABLE 305. ASEAN NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
TABLE 306. ASEAN NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
TABLE 307. ASEAN NEURODEGENERATIVE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 308. GCC NEURODEGENERATIVE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 309. GCC NEURODEGENE

Companies Mentioned

The key companies profiled in this Neurodegenerative Drugs market report include:
  • Abbott Laboratories
  • AbbVie Inc.
  • ACADIA Pharmaceuticals Inc.
  • Alpha Cognition Inc.
  • Amneal Pharmaceuticals, Inc.
  • Aquinnah Pharmaceuticals Inc.
  • Asceneuron SA
  • AstraZeneca PLC
  • AZTherapies, Inc.
  • Bausch Health Companies Inc.
  • Biogen Inc.
  • Boehringer Ingelheim International GmbH
  • Denali Therapeutics Inc.
  • Eli Lilly and Company
  • GlaxoSmithKline PLC
  • H. Lundbeck A/S
  • Johnson & Johnson Services, Inc.
  • Kyowa Kirin International plc
  • Lupin Limited
  • Merck & Co., Inc.
  • Novartis AG
  • Orion Corporation by Smiths Group plc
  • Pfizer, Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
  • Theravance Biopharma
  • UCB S.A.

Table Information

Report AttributeDetails
No. of Pages181
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 51.39 Billion
Forecasted Market Value ( USD ) by 2032 $ 81.51 Billion
Compound Annual Growth Rate7.9%
Regions CoveredGlobal
No. of Companies Mentioned28

Related Topics

Related Reports

Neurodegenerative Diseases Market - Global Forecast 2025-2032 - Product Image

Neurodegenerative Diseases Market - Global Forecast 2025-2032

  • Report
  • 183 Pages
  • Global
From
Neurodegenerative Drugs Market - Global Strategic Business Report - Product Image

Neurodegenerative Drugs Market - Global Strategic Business Report

  • Report
  • 376 Pages
  • Global
From
Neurodegenerative Diseases Drugs Market Report and Forecast 2025-2034 - Product Image

Neurodegenerative Diseases Drugs Market Report and Forecast 2025-2034

  • Report
  • 350 Pages
  • Global
From
Neurodegenerative Disorder Therapeutics Market Report 2025 - Product Image

Neurodegenerative Disorder Therapeutics Market Report 2025

  • Report
  • 250 Pages
  • Global
From
Neurodegenerative Diseases Therapeutics - Global Strategic Business Report - Product Image

Neurodegenerative Diseases Therapeutics - Global Strategic Business Report

  • Report
  • 387 Pages
  • Global
From

About the Market

The Neurodegenerative Disease Drug market is a subset of the Central Nervous System Drugs market, which focuses on treatments for diseases that cause the progressive loss of structure or function of neurons, including Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis (ALS). These drugs are typically used to slow the progression of the disease, improve symptoms, and improve quality of life. Common treatments include cholinesterase inhibitors, glutamate antagonists, and dopamine agonists. The Neurodegenerative Disease Drug market is highly competitive, with many large pharmaceutical companies vying for market share. Some of the major players in the market include Pfizer, Novartis, Merck, Sanofi, and Johnson & Johnson. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.